| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 199 | 129 | +54.6% |
| EBITDA | 3.1 | 6.3 | −51.6% |
| EBITDA margin | 1.5% | 4.9% | −3.4 pts |
| Profit before tax | −27.1 | −14.4 | — |
| Net profit | −26.0 | −16.2 | — |
| EPS | −₹7.39 | −₹5.26 | — |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 4,584 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 8.6 | 7.8 | 2.1 | 0.7 | 0.1 | ||
| 1.9 | 2.7 | 3.5 | 0.0 | — | ||
| 28.7 | 28.7 | 5.6 | 14.7 | 8.9 | ||
| 4,606 | — | — | — | — | ||
| 679 | 539 | 293 | 180 | 140 | ||
| — | +83.9% | +62.3% | +29.0% | — | ||
| −0.3 | 18.5 | −5.7 | 7.6 | 7.3 | ||
| −0.0% | 3.4% | −2.0% | 4.2% | 5.2% | ||
| −106 | −63.9 | −48.9 | −12.5 | −4.6 | ||
| −114 | −74.1 | −56.7 | −14.3 | −5.8 | ||
| −16.8% | −13.8% | −19.4% | −8.0% | −4.1% | ||
| −₹32.57 | −₹21.35 | −₹16.28 | −₹4.14 | −₹1.67 | ||
| — | −31.1% | −293.1% | −148.5% | — | ||
| — | −84.4 | −50.0 | −6.0 | −2.0 | ||
| — | 0.0 | 0.0 | 0.0 | −12.5 | ||
| −84.4 | −84.4 | −50.0 | −6.0 | −14.5 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 4,584.0 | |
| - Cash, Equiv & ST Investments | 0.1 | 0.7 | 2.1 | 7.8 | 8.6 | |
| + Minority Interest | — | 0.0 | 3.5 | 2.7 | 1.9 | |
| + Total Debt | 8.9 | 14.7 | 5.6 | 28.7 | 28.7 | |
| Enterprise Value | — | — | — | — | 4,606.0 | |
| Revenue | 140.0 | 180.5 | 293.0 | 538.7 | 679.1 | |
| Growth %, YoY | — | +29.0 | +62.3 | +83.9 | — | |
| EBITDA | 7.3 | 7.6 | -5.7 | 18.5 | -0.3 | |
| Margin % | 5.24 | 4.19 | -1.96 | 3.44 | -0.04 | |
| EBIT | -4.6 | -12.5 | -48.9 | -63.9 | -106.0 | |
| Net Income | -5.8 | -14.3 | -56.7 | -74.1 | -114.0 | |
| Margin % | -4.12 | -7.95 | -19.37 | -13.75 | -16.79 | |
| EPS, Adj (current shares) | -1.67 | -4.14 | -16.28 | -21.35 | -32.57 | |
| Growth %, YoY | — | -148.5 | -293.1 | -31.1 | — | |
| Cash from Operations | -2.0 | -6.0 | -50.0 | -84.4 | — | |
| Capital Expenditures | -12.5 | -0.0 | -0.0 | -0.0 | — | |
| Free Cash Flow | -14.5 | -6.0 | -50.0 | -84.4 | -84.4 | |
Prices at the 30 October 2026 close · figures from the company's filings with NSE
Zota Health Care (NSE: ZOTA) had a market capitalisation of ₹4,602 crore at the 30 October 2026 close (₹1,328.80 a share) and a price-to-book ratio of 7.36. In FY26 its consolidated net loss was ₹73.9 crore on revenue of ₹539 crore; in Q2 FY27 (July–September 2026) it was a loss of ₹25.6 crore. Its debt-to-equity ratio was 0.05 on 30 September 2026. Promoters held 49.38% of the shares on 30 September 2026.
Zota Health Care's PE ratio is not meaningful at the 30 October 2026 close: its consolidated net profit over the last four quarters (Q3 FY26 to Q2 FY27) was a loss of ₹113 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹4,602 crore at ₹1,328.80 a share.
Zota Health Care's price-to-book (PB) ratio is 7.36 at the 30 October 2026 close: a market capitalisation of ₹4,602 crore divided by shareholders' equity (book value) of ₹626 crore on 30 September 2026. That is a book value of ₹180.64 per share against a share price of ₹1,328.80.
Zota Health Care's debt-to-equity ratio was 0.05 on 30 September 2026: borrowings of ₹32 crore against total equity of ₹627 crore. A year earlier, on 30 September 2025, it was 0.02.
Zota Health Care's market capitalisation was ₹4,602 crore at the 30 October 2026 close: 3.46 crore shares at ₹1,328.80 each.
No. Zota Health Care had borrowings of ₹32 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.05. Its cash and current investments were ₹77.6 crore, so it held net cash of ₹45.5 crore.
In 2026, Zota Health Care has declared one dividend: ₹1 with record date 21 September 2026.
Zota Health Care's net worth — shareholders' equity in its consolidated balance sheet — was ₹626 crore on 30 September 2026, up 98.1% from ₹316 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,602 crore at the 30 October 2026 close.
Zota Health Care's book value per share was ₹180.64 on 30 September 2026: shareholders' equity of ₹626 crore divided by the 3.46 crore shares in issue. The share price at the 30 October 2026 close was ₹1,328.80.
In FY26, Zota Health Care generated ₹84.4 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹84.4 crore. In FY25 it was −₹50 crore.
In FY26, Zota Health Care's return on equity (ROE) was −16.1% and its return on capital employed (ROCE) was −10.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −36.0% and ROCE −19.8%.
On 30 September 2026, Zota Health Care's shares were held by promoters 49.38%, foreign portfolio investors (FII/FPI) 6.92%, domestic institutions (DII) 7.30% (including mutual funds at 0.37%) and retail and other non-institutional investors 36.40%. Over the year, FII holding was up 3.43 percentage points from 3.49% and DII holding was up 2.35 percentage points from 4.95%.
Zota Health Care's latest results are for Q2 FY27 (July–September 2026), filed on 28 October 2026: consolidated net loss ₹25.6 crore, wider than the loss of ₹15.9 crore in Q2 FY26; revenue from operations ₹199 crore, up 54.6% year on year.
Zota Health Care's basic earnings per share (EPS) were −₹22.46 in FY26, against −₹20.68 in FY25.
Promoters held 49.38% of Zota Health Care on 30 September 2026, unchanged from the previous quarter and down 6.43 percentage points from 55.81% a year earlier, according to the shareholding pattern filed with NSE.
In FY26 (April 2025–March 2026), Zota Health Care's consolidated net loss was ₹73.9 crore, wider than the loss of ₹56.4 crore in FY25, on revenue from operations of ₹539 crore (up 83.9%).
Zota Health Care has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
On FY26 consolidated figures, against Marine Electricals: Zota Health Care's operating margin of −11.9% is the lower of the two (Marine Electricals 9.1%; peer average 9.1%); its return on equity of −16.1% is the lower of the two (Marine Electricals 13.0%; peer average 13.0%); its revenue growth over three years of 56.7% a year is the higher of the two (Marine Electricals 25.6% a year; peer average 25.6% a year).
In FY26, Zota Health Care earned net profit of ₹73.9 crore on revenue of ₹539 crore, against ₹58.4 crore on ₹877 crore for Marine Electricals. Zota Health Care's operating margin was −11.9% (Marine Electricals 9.1%) and its return on equity −16.1% (Marine Electricals 13.0%). At the 30 October 2026 close, Zota Health Care's market capitalisation was ₹4,602 crore against ₹5,593 crore for Marine Electricals.
From Zota Health Care's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 30 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.